Experimental therapeutics with a new 10-deazaaminopterin in human mesothelioma: Further improving efficacy through structural design, pharmacologic modulation at the level of MRP ATPases, and combined therapy with platinums

Clinical Cancer Research

Volumn 7, Issue 10, 2001, Pages 3199-3205

  Khokhar, N Z ^a   She, Y ^a   Rusch, V W ^a   Sirotnak, F M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

10 DEAZAAMINOPTERIN; ADENOSINE TRIPHOSPHATASE; ANTINEOPLASTIC AGENT; CISPLATIN; EDATREXATE; FOLIC ACID DERIVATIVE; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN; OXOPLATIN; PLATINUM DERIVATIVE; PROBENECID;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; HUMAN; MESOTHELIOMA; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

ADENOSINE TRIPHOSPHATASES; AMINOPTERIN; ANIMALS; ANION TRANSPORT PROTEINS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CELL CYCLE PROTEINS; CELL DIVISION; CISPLATIN; DRUG DESIGN; FUNGAL PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITORY CONCENTRATION 50; MESOTHELIOMA; METHOTREXATE; MICE; MICE, NUDE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; PLATINUM COMPOUNDS; PROTEIN ISOFORMS; PROTEIN KINASES; RNA, NEOPLASM; SCHIZOSACCHAROMYCES POMBE PROTEINS; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0034798463     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Chemotherapy in malignant pleural mesothelioma: A review
2. Treatment of malignant pleural mesothelioma
3. Edatrexate (10-ethyl-10-deazaaminopterin; NSC626715) with and without leucovorin rescue for malignant mesothelioma: Sequential phase II trials of the cancer and leukemia group B. CALGB# 9131
4. New folate analogues of the 10-deazaaminopterin series. Basis for structural design and biochemical and pharmacologic properties
5. Selective antitumor action of folate analogues
6. New folate analogues of the 10-deazaaminopterin series. Markedly increased antitumor activity of the 10-ethyl analog compared to the parent compound and methotrexate against some human tumor xenografts in nude mice
7. Edatrexate, an antifolate with antitumor activity: A review
8. A new analogue of 10-deazaaminopterin with markedly enhanced curative effects against human tumor xenografts in mice
9. Phase I and pharmacokinetic study of 10-propargl-10-deazaaminopterin (PDX), a new antifolate
10. Co-administration of probenecid, an inhibitor of a cMOAT/MRP-like plasma membrane ATPase, greatly enhanced the efficacy of a new 10-deazaaminopterin against human solid tumors in vivo
11. The issues of transport multiplicity and energetics pertaining to methotrexate efflux in L1210 cells addressed by an analysis of cis and trans effects of inhibitors
12. Energy dependent efflux of methotrexate in L1210 leukemia cells. Evidence for the role of an ATPase obtained with inside-out plasma membrane vesicles
13. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5 homologues of the multidrug resistance associated protein gene (MRPI) in human cancer cell lines
14. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line
15. MOAT-4, a novel multispecific organic-anion transporter for glucuronides and mercapturates in mouse L1210 cells and human erythrocytes
16. Isolation of MOAT-B, a widely expressed multidrug resistance-associated protein/canicular multispecific organic anion transporter-related transporter
17. Expression of multidrug resistance protein 3 (multispecific organic transporter-b) in human embryonic kidney 293 cells confers resistance to anticancer agents
18. Characterization of MOAT-C and MOAT-D, new members of the MRP/cMOAT subfamily of transport proteins
19. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2
20. The multidrug resistance protein family
21. Analysis of the MRP4 drug resistance profile in transfected NIH3T3 cells
22. Molecular cloning of a cannicular multispecific organic anion transporter defective in EHBR
23. Carboplatin versus cisplatin in solid tumors: An analysis of the literature
24. Review of comparative pharmacology and clinical activity of cisplatin and carboplatin
25. CpG island hypermethylation in human colorectal tumors is not associated with DNA methyltransferase overexpression
26. MOAT-E (ARA) is a full-length MRP/cMOAT subfamily transporter expressed in kidney and liver
27. Expression of human MRP6, a homologue of the multidrug resistance protein gene MRPI, in tissues and cancer cells
28. Analysis of the structure and expression pattern of MRP7 (ABCC10), a new member of the MRP subfamily
29. Real-time quantitative RT-PCR after laser-assisted cell picking
30. Interleukin 8 messenger ribonucleic acid expression correlates with tumor progression, tumor angiogenesis, patient survival and timing of relapse in non-small-cell-lung cancer
31. Similar differential for total polyglutmylation and cytotoxicity among various folate analogues in human and murine tumor cell lines in vitro